Abstract | INTRODUCTION:
Breakthrough pain, a transitory flare of pain in patients with otherwise controlled chronic pain, has been well characterized in cancer patients but despite medical awareness, sometimes remains underdiagnosed and therefore undertreated. AREAS COVERED: EXPERT OPINION: The aim of this review is to summarize the pharmacological characteristics and data obtained from clinical studies of INFS in the past few years, and present Fentanyl Pectin Nasal Spray (PecFent), which uses an innovative delivery system and is now approved in the EU. Finally, we discuss the impact that it may have in the future management of breakthrough pain in cancer patients, because an accurate diagnosis followed by the best treatment is crucial for effective pain alleviation.
|
Authors | Kyriaki Mystakidou, Irene Panagiotou, Athanasios Gouliamos |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 12
Issue 10
Pg. 1653-9
(Jul 2011)
ISSN: 1744-7666 [Electronic] England |
PMID | 21609189
(Publication Type: Comparative Study, Journal Article, Review)
|
Copyright | © 2011 Informa UK, Ltd. |
Chemical References |
- Analgesics, Opioid
- Nasal Sprays
- Pectins
- Fentanyl
|
Topics |
- Administration, Intranasal
- Administration, Oral
- Analgesics, Opioid
(administration & dosage, pharmacokinetics, therapeutic use)
- Drug Delivery Systems
- Fentanyl
(administration & dosage, pharmacokinetics, therapeutic use)
- Humans
- Nasal Sprays
- Neoplasms
(complications)
- Pain
(drug therapy, etiology)
- Pectins
(chemistry)
|